Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs
- PMID: 33132211
- PMCID: PMC7607594
- DOI: 10.1136/bmjdrc-2020-001540
Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs
Abstract
Introduction: The insulinotropic capacity of exogenous glucagon like peptide-1 (GLP-1) is reduced in type 2 diabetes and the insulin-resistant obese. We have tested the hypothesis that this response is the consequence of a reduced pancreatic GLP-1 receptor (GLP-1r) density in insulin-resistant obese animals.
Research design and methods: GLP-1r density was measured in lean and insulin-resistant adult miniature pigs after the administration of a 68Ga-labeled GLP-1r agonist. The effect of hyperinsulinemia on GLP-1r was assessed using sequential positron emission tomography (PET), both in the fasted state and during a clamp. The impact of tissue perfusion, which could account for changes in GLP-1r agonist uptake, was also investigated using 68Ga-DOTA imaging.
Results: GLP-1r binding potential in the obese pancreas was reduced by 75% compared with lean animals. Similar reductions were evident for fat tissue, but not for the duodenum. In the lean group, induced hyperinsulinemia reduced pancreatic GLP-1r density to a level comparable with that of the obese group. The reduction in blood to tissue transfer of the GLP-1r ligand paralleled that of tissue perfusion estimated using 68Ga-DOTA.
Conclusions: These observations establish that a reduction in abdominal tissue perfusion and a lower GLP-1r density account for the diminished insulinotropic effect of GLP-1 agonists in type 2 diabetes.
Keywords: animal experimentation; glucagon-like peptide 1; insulin resistance; positron-emission tomography.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures





Similar articles
-
Exploring the GLP-1-GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography.BMJ Open Diabetes Res Care. 2021 Apr;9(1):e002083. doi: 10.1136/bmjdrc-2020-002083. BMJ Open Diabetes Res Care. 2021. PMID: 33903116 Free PMC article.
-
18F-Labeled exendin(9-39).2012 Feb 9 [updated 2012 May 17]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 Feb 9 [updated 2012 May 17]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 22624171 Free Books & Documents. Review.
-
Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.Diabetes Obes Metab. 2017 May;19(5):705-712. doi: 10.1111/dom.12879. Epub 2017 Mar 10. Diabetes Obes Metab. 2017. PMID: 28094469
-
Glucose Sensing Mediated by Portal Glucagon-Like Peptide 1 Receptor Is Markedly Impaired in Insulin-Resistant Obese Animals.Diabetes. 2021 Jan;70(1):99-110. doi: 10.2337/db20-0361. Epub 2020 Oct 16. Diabetes. 2021. PMID: 33067312
-
Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.Peptides. 2018 Feb;100:94-100. doi: 10.1016/j.peptides.2017.12.005. Peptides. 2018. PMID: 29412838 Review.
Cited by
-
Vagally Mediated Gut-Brain Relationships in Appetite Control-Insights from Porcine Studies.Nutrients. 2021 Jan 30;13(2):467. doi: 10.3390/nu13020467. Nutrients. 2021. PMID: 33573329 Free PMC article. Review.
-
Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling: Making the Case for a Functionally Gs Protein-Selective GPCR.Int J Mol Sci. 2025 Jul 26;26(15):7239. doi: 10.3390/ijms26157239. Int J Mol Sci. 2025. PMID: 40806371 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases